GENELINK (GNLK) PROFILED AND RECOMMENDED BY DIRIGO RESEARCH
March 27, 2002

Margate, NJ-(BUSINESS WIRE)-- March 26, 2002 - GeneLink BioSciences, Inc. (OTCBB:GNLK) has recently been profiled and recommended by Dirigo Research of Camden, Maine. The two page report may be found on the Dirigo website at www.dirigoresearch.com or on the GeneLink corporate websites at www.genelink.info

In the Report, Dirigo's recommendation states that "GeneLink is finalizing marketing and distribution agreements now with some of the world's largest distributors of nutritional, skin care, personal care, wellness and anti-aging products, and we expect to see both revenues and profits soon. In our judgment, GNLK will move much higher as the Company's story becomes better known on the Street."

About GeneLink BioSciences, Inc.: GNLK is positioned to become a leading provider of genetic profiling technologies. It developed a proprietary method for "genetic profiling" (patents pending) & will begin licensing this breakthrough technology to companies that market or manufacture products for the $100 billion plus nutraceutical, skin care, wellness, & weight-loss industries. GNLK has an FDA cleared & patented non-invasive DNA Collection Kit. Its DNA bank is located at the University of North Texas Health Science Center at Fort Worth, a 105-year-old medical facility that guarantees the DNA storage. For more information, visit GeneLink's website www.genelink.info.

About Dirigo Research: Dirigo Research has been a "publishing advisory service" since 1966. Since 1985, the firm has concentrated on low priced securities. Their stated goal is to report on six to eight "special situation" stocks a year in search of "really big winners" and report on them with "a fast reading, hard hitting, factual, up-to-the minute report". "The stocks we recommend move independently of the DJIA So we and our readers don't have to be concerned with hourly market swings", says Dirigo.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.